Please Note: This trial is no longer enrolling new participants
A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) rosopatamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen Receptor Pathway Inhibitor Treatment
| Protocol No. | CTO-177LU-TLX591-203 | Scope | National |
|---|---|---|---|
| Principal Investigator | Nabil Adra | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
